Adaptive Biotechnologies raises 2026 MRD revenue view to $260M-$270M while targeting positive adjusted EBITDA and free cash flow by end of 2026
ORIGINAL SOURCE →via Seeking Alpha
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] Smotrich's October 7 comments should disgust every single one of us - editorial
- [CONFLICT] Backlash grows over Israeli character in R.F. Kuang’s upcoming novel 'Taipei Story'
- [CONFLICT] Australia says Islamic State-linked citizens in Syria camp plan to return home
- [CONFLICT] Toyota Hino debut new Le Series electric MD trucks at ACT Expo